Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5312 in advanced solid tumours
NCT02144051Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2014
- Primary completion
- Mar 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of AZD5312 in solid tumor, metastatic castration-resistant prostate cancer (mCRPC), breast cancer and 4 more, sponsored by AstraZeneca. Primary endpoints: Maximum Tolerated Dose at 13 months, Safety and tolerability at 13 months and 1 more. Started May 2014; status: completed.
02
Drugs
AZD5312
03
Conditions
solid tumormetastatic castration-resistant prostate cancer (mCRPC)breast cancerbladder cancerovarian cancer
Beyond the preview
Go deeper on NCT02144051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02144051.